[1]唐婷 陈明.心力衰竭合并贫血和铁缺乏的诊治进展[J].心血管病学进展,2020,(5):499-503.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
 TANG Ting,CHEN Ming.Diagnosis and Treatment of Anemia and Iron Deficiency in Heart Failure[J].Advances in Cardiovascular Diseases,2020,(5):499-503.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
点击复制

心力衰竭合并贫血和铁缺乏的诊治进展()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年5期
页码:
499-503
栏目:
出版日期:
2020-05-25

文章信息/Info

Title:
Diagnosis and Treatment of Anemia and Iron Deficiency in Heart Failure
作者:
唐婷1 陈明2
(1.重庆医科大学附属第一医院,重庆 400016;2.重庆医科大学附属第一医院心血管内科,重庆 400016)
Author(s):
TANG Ting1CHEN Ming2
(1.The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China; 2.Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
心力衰竭贫血铁缺乏
Keywords:
Heart failure Anemia Iron deficiency
DOI:
10.16806/j.cnki.issn.1004-3934.2019.05.014
摘要:
心力衰竭(心衰)是所有心脏疾病的严重表现或晚期阶段,目前心衰的发病机制和治疗已有显著进展,预后得到改善,但仍不容乐观。贫血和铁缺乏是心衰常见的合并症,无论共存或独立,都与心衰预后不良有关。积极纠正贫血和铁缺乏有助于改善心衰患者症状和提高生活质量。红细胞生成刺激剂常用于心衰患者贫血的纠正,但并未改善预后,且增加不良事件风险。口服补铁方便易得,静脉补铁能改善心衰症状和运动能力,但两者的长期疗效和安全性需进一步研究。
Abstract:
Heart failure is the severe manifestation or advanced stage of all heart diseases.At present, the pathogenesis and treatment of heart failure have already made significant progress, and the prognosis has improved, but it is still not optimistic.Anemia and iron deficiency are common combinations of heart failure.Both conditions, together or independently, are associated with poor prognosis for heart failure. Actively correcting anemia and iron deficiency can help improve symptoms and quality of life in patients with heart failure. Erythropoiesis-stimulating agents are commonly used to correct anemia in patients with heart failure, but they do not improve prognosis and increase the risk of adverse events. Oral iron supplementation is convenient and readily available, and intravenous iron supplementation can improve symptoms and exercise capacity, but the long-term efficacy and safety of both need further study

参考文献/References:

[1]Triposkiadis F,Giamouzis G,Parissis J,et al.Reframing the association and significance of co-morbidities in heart failure[J].Eur J Heart Fail,2016,18(7):744-758.

[2]Cleland JG,Zhang J,Pellicori P,et al.Prevalence and outcomes of anemia and hematinic deficiencies in patients with chronic heart failure[J].JAMA Cardiol,2016,1(5):539-547.

[3]Anand IS,Gupta P.Anemia and iron deficiency in heart failure:current concepts and emerging therapies[J].Circulation,2018,138(1):80-98.

[4]Ganz T.Hepcidin and iron regulation,10 years later[J].Blood,2011,117(17):4425-4433.

[5]袁丽君,孔一慧.贫血或铁缺乏与慢性心力衰竭[J].心血管病学进展,2018,39(3):402-407.

[6]Montero D,Lundby C,Ruschitzka F,et al.True anemia-red blood cell volume deficit-in heart failure:a systematic review[J].Circ Heart Fail,2017,10(5).

[7]Magri D,de Martino F,Moscucci F,et al.Anemia and iron deficiency in heart failure:clinical and prognostic role[J].Heart Fail Clin,2019,15(3):359-369.

[8]Cattadori G,Agostoni P,Corrà U,et al.Heart failure and anemia effects on prognostic variables[J].Eur J Intern Med,2017,37 :56-63.

[9]Díez-López C,Lupón J,de Antonio M,et al.Hemoglobin kinetics and long-term prognosis in heart failure[J].Rev Esp Cardiol (Engl Ed),2016,69(9):820-826.

[10]Anand IS,Kuskowski MA,Rector TS,et al.Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure:results from Val-HeFT[J].Circulation,2005,112(8):1121-1127.

[11]Mazer CD,Whitlock RP,Fergusson DA,et al.Restrictive or liberal red-cell transfusion for cardiac surgery[J].N Engl J Med,2017,377(22):2133-2144.

[12]Akbari A,Clase CM,Acott P,et al.Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management[J].Am J Kidney Dis,2015,65(2):177-205.

[13]Swedberg K,Young JB,Anand IS,et al.Treatment of anemia with darbepoetin alfa in systolic heart failure[J].N Engl J Med,2013,368(13):1210-1219.

[14]Yancy CW,Jessup M,Bozkurt B,et al.2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America[J].Circulation,2017,136(6):e137-e161.

[15]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225.

[16]Lopez A,Cacoub P,Macdougall IC,et al.Iron deficiency anaemia[J].Lancet,2016,387(10021):907-916.

[17]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J].Eur J Heart Fail,2016,18(8):891-975.

[18]Rocha BML,Cunha GJL,Menezes Falc?o LF.The burden of iron deficiency in heart failure: therapeutic approach[J].J Am Coll Cardiol,2018,71(7):782-793.

[19]Stugiewicz M,Tkaczyszyn M,Kasztura M,et al.The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications[J].Eur J Heart Fail,2016,18(7):762-773.

[20]Dziegala M,Josiak K,Kasztura M,et al.Iron deficiency as energetic insult to skeletal muscle in chronic diseases[J].J Cachexia Sarcopenia Muscle,2018,9(5):802-815.

[21]Xu W,Barrientos T,Mao L,et al.Lethal cardiomyopathy in mice lacking transferrin receptor in the heart[J].Cell Rep,2015,13(3):533-545.

[22]Nikolaou M,Chrysohoou C,Georgilas TA,et al.Management of iron deficiency in chronic heart failure:practical considerations for clinical use and future directions[J].Eur J Intern Med,2019,65:17-25.

[23]Charles-Edwards G,Amaral N,Sleigh A,et al.Effect of iron isomaltoside on skeletal muscle energetics in patients with chronic heart failure and iron deficiency[J].Circulation,2019,139(21):2386-2398.

[24]Martens P,Nijst P,Verbrugge FH,et al.Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction[J].Acta Cardiol,2018,73(2):115-123.

[25]Jankowska EA,Rozentryt P,Witkowska A,et al.Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure[J].J Card Fail,2011,17(11):899-906.

[26]Bekfani T,Pellicori P,Morris D,et al.Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life[J].Clin Res Cardiol,2019,108(2):203-211.

[27]Ponikowski P,van Veldhuisen DJ,Comin-Colet J,et al.Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencydagger[J].Eur Heart J,2015,36(11):657-668.

[28]van Veldhuisen DJ,Ponikowski P,van der Meer P,et al.Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency[J].Circulation,2017,136(15):1374-1383.

[29]Anker SD,Kirwan BA,van Veldhuisen DJ,et al.Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients:an individual patient data meta-analysis[J].Eur J Heart Fail,2018,20(1):125-133.

[30]Lewis GD,Malhotra R,Hernandez AF,et al.Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency:the IRONOUT HF randomized clinical trial[J].JAMA,2017,317(19):1958-1966.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
 DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
 LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
 ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
 LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
 KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
 SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
 XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
 GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
 HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
 WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2020-08-12